I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Juno Therapeutics (JUNO) proposes $225 M follow-on offering

September 20, 2017

Shares closed up +$1.41 or +3.22 to $45.21 while the aftermarket drops -$1.95 or -4.31% 106,32 M shares outstanding a float of 70.66 M and a BIG shirt position of 15.43 M shares and 697.62 M in cash, 10 M indebtbut 82,57 M in revenue

VistaGen (VTGN) prices 1.37 M share offering at $1.75 with 1.89 M warrants attached

August 31, 2017

VTGN is down -$0.10 or -5.50% to $1.72 ​A little heavy on the warrants to raise $2.4 million ...?  

Histogenics (HSGX) P3 Clinical Trial of Neocart® enrollment completed to Treat Knee Cartilage Damage - BUY

June 27, 2017

On track for top-line 1 year powered data and potential BLA filing in Q3/18 BLA to the FDA shortly thereafter and, if approved, launching NeoCart in the second half of 2019  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.